CA2904432A1 - High drug load buprenorphine microspheres and method of producing the same - Google Patents

High drug load buprenorphine microspheres and method of producing the same Download PDF

Info

Publication number
CA2904432A1
CA2904432A1 CA2904432A CA2904432A CA2904432A1 CA 2904432 A1 CA2904432 A1 CA 2904432A1 CA 2904432 A CA2904432 A CA 2904432A CA 2904432 A CA2904432 A CA 2904432A CA 2904432 A1 CA2904432 A1 CA 2904432A1
Authority
CA
Canada
Prior art keywords
buprenorphine
phase
formulation
solvent
dispersed phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2904432A
Other languages
English (en)
French (fr)
Inventor
Bagavathikanun Chithambara Thanoo
Tracy RICHEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of CA2904432A1 publication Critical patent/CA2904432A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2904432A 2013-03-15 2014-03-14 High drug load buprenorphine microspheres and method of producing the same Abandoned CA2904432A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/837,181 US9393211B2 (en) 2013-03-15 2013-03-15 High drug load buprenorphine microspheres and method of producing same
US13/837,181 2013-03-15
PCT/US2014/027982 WO2014143839A1 (en) 2013-03-15 2014-03-14 High drug load buprenorphine microspheres and method of producing the same

Publications (1)

Publication Number Publication Date
CA2904432A1 true CA2904432A1 (en) 2014-09-18

Family

ID=51528078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904432A Abandoned CA2904432A1 (en) 2013-03-15 2014-03-14 High drug load buprenorphine microspheres and method of producing the same

Country Status (9)

Country Link
US (1) US9393211B2 (enExample)
EP (1) EP2968577B1 (enExample)
JP (1) JP6678571B2 (enExample)
CN (1) CN105377301B (enExample)
BR (1) BR112015022985A2 (enExample)
CA (1) CA2904432A1 (enExample)
ES (1) ES2717942T3 (enExample)
MX (1) MX362709B (enExample)
WO (1) WO2014143839A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
US9636308B2 (en) * 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20170065579A1 (en) * 2015-09-08 2017-03-09 Andreas Voigt Sustained Release Low Dose Formulations and Uses Thereof
CN105596298B (zh) * 2015-12-18 2018-08-14 山东大学 一种包载丁丙诺啡的peg-plga缓释微球及其制备方法
CA3015488A1 (en) * 2016-02-23 2017-08-31 Biodelivery Sciences International, Inc. Sustained release buprenorphine microspheres (srbm) and methods of use thereof
PL3512518T3 (pl) 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
TWI838372B (zh) 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
CN115605187B (zh) * 2020-02-26 2024-09-17 福多兹制药公司 载有孕激素药物的可注射控释制剂
CA3210098A1 (en) 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN114392384B (zh) * 2021-12-24 2023-04-11 河南驼人医疗器械研究院有限公司 一种制备高载药量栓塞微球的方法及收集装置
CN115317453A (zh) * 2022-09-01 2022-11-11 广东嘉博制药有限公司 一种缓释微球制剂及其制备方法与用途
EP4611729A1 (en) * 2022-10-31 2025-09-10 Oakwood Laboratories, LLC Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2382577C (en) 1999-08-27 2008-01-22 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
EP1555023A3 (en) * 1999-08-27 2005-09-28 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US20050048115A1 (en) 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
TWI362947B (en) 2007-03-08 2012-05-01 Univ Kaohsiung Medical Controlled release pharmaceutical composition and manufacture method thereof
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
US20100086597A1 (en) 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
WO2011087496A1 (en) 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
JP6678571B2 (ja) 2020-04-08
US9393211B2 (en) 2016-07-19
JP2016513721A (ja) 2016-05-16
MX2015012232A (es) 2015-12-01
CN105377301B (zh) 2020-06-05
MX362709B (es) 2019-02-05
CN105377301A (zh) 2016-03-02
EP2968577A1 (en) 2016-01-20
EP2968577A4 (en) 2016-11-23
US20140271869A1 (en) 2014-09-18
BR112015022985A2 (pt) 2017-08-22
ES2717942T3 (es) 2019-06-26
WO2014143839A1 (en) 2014-09-18
EP2968577B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
US9393211B2 (en) High drug load buprenorphine microspheres and method of producing same
US9636308B2 (en) High drug load buprenorphine microspheres and method of producing same
JP7038741B2 (ja) 放出制御が容易な徐放性薬物微粒子の製造方法
JP2016513721A5 (enExample)
US11992559B2 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
EP4199917B1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
US20250032451A1 (en) Microsphere formulations comprising asenapine and methods for making and using the same
ES3061392T3 (en) Microsphere formulations comprising ketamine and methods for making and using the same
JP2026507990A (ja) オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法
US20240307381A1 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
WO2025117624A1 (en) Microsphere formulations comprising brexpiprazole and methods for making and using the same
CN116916893A (zh) 包含btk抑制剂的微球制剂及其制备和使用方法
CA3294255A1 (en) Sustained-release microsphere preparation comprising tirzepatide or pharmaceutically acceptable salt thereof and method for preparing same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190226

FZDE Discontinued

Effective date: 20220412